Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma

Craig H. Moskowitz, Jill R. Glassman, David Wuest, Peter Maslak, Lilian Reich, Anthony Gucciardo, Nancy Coady-Lyons, Andrew D. Zelenetz, Stephen D. Nimer

Research output: Contribution to journalArticle

114 Scopus citations


The objective of this study was to identify factors associated with poor mobilization of peripheral blood progenitor cells (PBPCs) or delayed platelet engraftment after high-dose therapy and autologous stem cell transplantation in patients with lymphoma. Fifty-eight patients with Hodgkin's disease or non-Hodgkin's lymphoma underwent PBPC transplantation as the 'best available therapy' at Memorial Sloan-Kettering Cancer Center (New York, NY) between 1993 and 1995. PBPCs were mobilized with either granulocyte colony- stimulating factor (G-CSF) alone (n = 19) or G-CSF following combination chemotherapy (n = 39). Forty-eight of these patients underwent a PBPC transplant, receiving a conditioning regimen containing cyclophosphamide, etoposide, and either total body irradiation, total lymphoid irradiation, or carmustine. A median number of 4.6 x 106 CD34+ cells/kg were obtained with a median of three leukapheresis procedures. Mobilization of PBPCs using chemotherapy plus G-CSF was superior to G-CSF alone (6.7 x 106 versus 1.5 x 106 CD34+ cells/kg; P = 0.0002). Poorer mobilization of progenitor cells was observed in patients who had previously received stem cell-toxic chemotherapy, including (a) nitrogen mustard, procarbazine, melphalan, carmustine or >7.5 g of cytarabine chemotherapy premobilization (2.0 x 106 versus 6.0 x 106 CD34+ cells/kg; P = 0.005), or (b) ≤11 cycles of any previous chemotherapy (2.6 x 106 versus 6.7 x 106 CD34+ cells/kg; P = 0.02). Platelet recovery to >20,000/μl was delayed in patients who received <2.0 x 106 CD34+ cells (median, 13 versus 22 days; P = 0.06). Patients who received ≤11 cycles of chemotherapy prior to PBPC mobilization tended to have delayed platelet recovery to > 20,000/μl and to require more platelet transfusions than less extensively pretreated patients (median, 13.5 versus 23.5 days; P = 0.15; median number of platelet transfusion episodes, 13 versus 9; P = 0.17). These data suggest that current strategies to mobilize PBPCs may be suboptimal in patients who have received either stem cell-toxic chemotherapy or ≤11 cycles of chemotherapy prior to PBPC mobilization. Alternative approaches, such as ex vivo expansion or the use of other growth factors in addition to G-CSF, may improve mobilization of progenitor cells for PBPC transplantation.

Original languageEnglish (US)
Pages (from-to)311-316
Number of pages6
JournalClinical Cancer Research
Issue number2
StatePublished - Feb 1 1998
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma'. Together they form a unique fingerprint.

  • Cite this

    Moskowitz, C. H., Glassman, J. R., Wuest, D., Maslak, P., Reich, L., Gucciardo, A., Coady-Lyons, N., Zelenetz, A. D., & Nimer, S. D. (1998). Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clinical Cancer Research, 4(2), 311-316.